培美曲塞联合顺铂一线治疗晚期肺腺癌的临床研究.pdf

《培美曲塞联合顺铂一线治疗晚期肺腺癌的临床研究.pdf》由会员上传分享，免费在线阅读，更多相关内容在行业资料-天天文库。

1、766中国临床研究2013年8月第26卷第8期ChineseJournalofClinicalResearch，August2013，Vo1．26，No．8·论著·培美曲塞联合顺铂一线治疗晚期肺腺癌的临床研究王文明，李绪彤，秦琛【摘要】目的比较培美曲塞联合顺铂与多西他赛联合顺铂一线治疗晚期肺腺癌的近期疗效、无进展生存期及毒副反应。方法76例晚期肺腺癌(ⅢB／Ⅳ期)患者随机分为培美曲塞联合顺铂(PC)组和多西他赛联合顺铂(DC)组，每组各38例。Pc组：培美曲塞500mg／m，dl；DC组：多西他赛75

2、ms／m，dl。两组顺铂均为25ms／m，dl一3；每21d为1个周期。两组均治疗2周期后评价疗效及毒副反应。对所有患者的近期疗效、1年生存率、无进展生存期及毒副反应进行随访及组间比较。结果PC组近期有效率为42．I％，中位无进展生存期6．9月，1年生存率55．3％；DC组近期有效率为36．8％，中位无进展生存期6．2月。1年生存率47．4％；两组比较差异均无统计学意义(P均>0．05)。PC组患者Ⅲ～IV度血液学毒性发生率明显低于DC组患者(P<0．05)。结论培美曲塞联合顺铂一线治疗晚期肺腺癌有稳

3、定的疗效，更低的毒副反应。【关键词l肺腺癌；化学治疗；培美曲塞；多西他赛；顺铂中图分类号：R734．2R730．53文献标识码：A文章编号：1674—8182(2013)08—0766—03Clinicalstudyofpemetrexedcombinedthcisplatinasthefirst-linetreatmentforadvancedlungadenocarcinomaWANGWen—ming．LIXu-tong．QlNChen．DepartmentofOncology．theSecond

4、AffiliatedHospital，MedicalCollegeofQingdaoUniversity，Qingdao，ShandongProvince266042，China【Abstract】ObjectiveTocomparetheclinicalefficacy，progression—freesurvival(PFS)timeandtoxicityofpemetrexedcombinedwithcisplatinanddocetaxelcombinedwithcisplatinintrea

5、tingadvancedlungadenocareinoma．MethodsSeventy·sixpatientswithadvancedlungadenocareinoma(stagemB／Ⅳ)wereenrolledinthisstudy．Thesepatientswererandomlydividedintotwogroups(n=38each)：PCgroup(pemetrexedpluscisplatin)andDCgroup(docetaxelpluscisplatin)．Patients

6、inthePCgroupwereadministeredwith500ms／mpeme~exedonday1，andpatientsintheDCgroupwereadministeredwith75ms／mdoeetaxelonday1．Bothgroupswerevencisplatin25ms／monday1，2and3．Thetreatmentswererepeatedevery21days．Theshorttermeficacyandtoxicityofpatientswerealleval

7、uatedaftertwocycles．PFStimeand1·yearsurvivalrateofallpatientswerefollowedupandcomparedbetweengroups．ResultsTheshort—termtotaleffectiverateofthePCgroupandtheDCgroupwere42．1％and36．8％respectively；medianPFStimewas6．9monthsinthePCgroupand6．2monthsintheDCgrou

8、p：one—yearsurvivalratewas55．3％inPCgroupand47．4％inDCgroup．Therewasnosignificantdifferenceofshorttermeficacy，medianPFStimeand1-yearsurvivalratebetweenthetwogroups(allP>0．05)．TheincidenceofhematologictoxicitiesofthegradeIlB／ⅣinthePC